AZNCF
AstraZeneca PlcOTCPK - Current
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, Jul. 28, 5:50 AM
    • AstraZeneca (NYSE:AZN): Q2 EPS of $0.83 beats by $0.07.
    • Revenue of $5.6B (-11.3% Y/Y) beats by $40M.
    • Shares +1.05% PM.
    • Press Release
    | Thu, Jul. 28, 5:50 AM | 1 Comment
  • Aug. 19, 2014, 4:45 AM
    • AstraZeneca (NYSE:AZN) says that the U.S. government has closed a probe that investigated a major clinical trial used to win marketing approval for the company's new heart drug Brilinta.
    • Following the DOJ's investigation into the study last October, doubts have ensued over the medicine's future success.
    • AstraZeneca argues that Brilinta can bring in $3.5B in annual sales, although until now the drug has not made any record performance.
    | Aug. 19, 2014, 4:45 AM